File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Current antiviral therapy of chronic hepatitis B: Efficacy and safety

TitleCurrent antiviral therapy of chronic hepatitis B: Efficacy and safety
Authors
KeywordsHBV DNA
Hepatitis B
Nucleos(t)ide Analogs
Resistance
Issue Date2011
PublisherSpringer Healthcare. The Journal's web site is located at http://www.springerlink.com/content/1540-3416/
Citation
Current Hepatitis Reports, 2011, v. 10 n. 4, p. 235-243 How to Cite?
AbstractThe treatment of chronic hepatitis B is in constant evolution. Interferon, the first agent licensed for chronic hepatitis B treatment, has been superseded by the growing popularity of nucleoside/nucleotide analogues (NA). However, resistance to these agents is a major challenge. Newer NAs, such as entecavir and tenofovir dipivoxil fumarate, have very low resistance rates and favorable safety profiles. Long-term use of these agents can effectively suppress hepatitis B virus DNA, leading to decrease in incidence of hepatitic flares, as well as in the development of cirrhosis and hepatocellular carcinoma. The efficacy and safety of various antiviral agents is discussed in this review. © 2011 The Author(s).
Persistent Identifierhttp://hdl.handle.net/10722/144892
ISSN
2015 SCImago Journal Rankings: 0.215
PubMed Central ID
References

 

DC FieldValueLanguage
dc.contributor.authorLam, YFen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorSeto, WKen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2012-02-21T05:44:09Z-
dc.date.available2012-02-21T05:44:09Z-
dc.date.issued2011en_HK
dc.identifier.citationCurrent Hepatitis Reports, 2011, v. 10 n. 4, p. 235-243en_HK
dc.identifier.issn1540-3416en_HK
dc.identifier.urihttp://hdl.handle.net/10722/144892-
dc.description.abstractThe treatment of chronic hepatitis B is in constant evolution. Interferon, the first agent licensed for chronic hepatitis B treatment, has been superseded by the growing popularity of nucleoside/nucleotide analogues (NA). However, resistance to these agents is a major challenge. Newer NAs, such as entecavir and tenofovir dipivoxil fumarate, have very low resistance rates and favorable safety profiles. Long-term use of these agents can effectively suppress hepatitis B virus DNA, leading to decrease in incidence of hepatitic flares, as well as in the development of cirrhosis and hepatocellular carcinoma. The efficacy and safety of various antiviral agents is discussed in this review. © 2011 The Author(s).en_HK
dc.languageengen_US
dc.publisherSpringer Healthcare. The Journal's web site is located at http://www.springerlink.com/content/1540-3416/en_HK
dc.relation.ispartofCurrent Hepatitis Reportsen_HK
dc.rightsThe Author(s)en_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong Licenseen_US
dc.subjectHBV DNAen_HK
dc.subjectHepatitis Ben_HK
dc.subjectNucleos(t)ide Analogsen_HK
dc.subjectResistanceen_HK
dc.titleCurrent antiviral therapy of chronic hepatitis B: Efficacy and safetyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4551/resserv?sid=springerlink&genre=article&atitle=Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety&title=Current Hepatitis Reports&issn=15403416&date=2011-12-01&volume=10&issue=4& spage=235&authors=Yuk-Fai Lam, Man-Fung Yuen, Wai-Kay Seto, <i>et al.</i>en_US
dc.identifier.emailYuen, MF: mfyuen@hku.hken_HK
dc.identifier.emailSeto, WK: wkseto2@hku.hken_HK
dc.identifier.emailLai, CL: hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authoritySeto, WK=rp01659en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1007/s11901-011-0109-zen_HK
dc.identifier.pmid22131901-
dc.identifier.pmcidPMC3210946-
dc.identifier.scopuseid_2-s2.0-81355147539en_HK
dc.identifier.hkuros210690-
dc.identifier.hkuros208899-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81355147539&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue4en_HK
dc.identifier.spage235en_HK
dc.identifier.epage243en_HK
dc.identifier.eissn1541-0706en_US
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 21 Feb 2012en_US
dc.identifier.scopusauthoridLam, YF=45661458000en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridSeto, WK=23390675900en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.citeulike9686292-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats